This activity has expired. Credit is no longer available.
This activity is supported by independent educational grants from Merck Sharp & Dohme Corp, Novartis Pharmaceuticals Corporation, Puma Biotechnology, Takeda Oncology.

New Drug Updates in Hematologic Malignancies: CAR T Cells, Targeted Therapeutics, and Other Agents

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA
Emory University and Winship Cancer Institute

Get an update on the fast-changing world of therapies for hematologic malignancies. With the constantly growing list of new drugs and indications, as well as the introduction of cutting-edge CAR T-cell therapy for the treatment of hematologic malignancies, it’s important that advanced practitioners stay up to date on the latest advances to be able to adequately diagnose, treat, and help patients navigate potential side effects.



 

Download Transcript

 
 

Download Slides


 
These activities, certified for CME/CE/CPE credit, are jointly provided by

Annenberg Logo Harborside Press Logo

in collaboration with

JADPRO CE Logo APSHO Logo
Copyright © 2010-2019 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.